#United States #Cranford #LYMPHIR #Citius Oncology #McKesson

Citius Oncology Partners with McKesson for LYMPHIR™ Distribution

Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, announced on October 20, 2025, a significant step in its distribution strategy with the signing of an agreement with McKesson Corporation. As one of the largest pharmaceutical distributors in North America, McKesson will serve as the authorized distributor of LYMPHIR (denileukin diftitox-cxdl), an innovative immunotherapy recently approved by the FDA for the treatment of patients suffering from relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

This agreement not only strengthens Citius Oncology's distribution network but also signifies the completion of its core strategy to ensure comprehensive access to LYMPHIR across the United States. With McKesson joining other major pharmaceutical distributors in the network, Citius aims to enhance availability of this crucial therapy to both academic and community oncology practices.

About the Agreement

Leonard Mazur, the Chairman and CEO of Citius, noted that this partnership is a testament to their commitment to streamline access to LYMPHIR for healthcare professionals and patients alike. With the goal of a successful launch anticipated in the fourth quarter of 2025, having a robust distribution network in place is critical in addressing the needs of the CTCL community.

McKesson, headquartered in Irving, Texas, plays a pivotal role in the healthcare supply chain by providing a wide range of services, including the distribution of pharmaceutical products to hospitals, clinics, and pharmacies. This relationship ensures that LYMPHIR will be more readily available to those who need it most.

In tandem with the distribution agreement, Citius is actively preparing for the commercial launch by focusing on several key areas. These include ensuring inventory readiness, establishing a solid market access infrastructure, and providing educational resources for both providers and patients involved in the treatment process of CTCL.

Understanding LYMPHIR™

LYMPHIR is a targeted immunotherapy designed to attack the IL-2 receptors found on the surface of certain cancerous T-cells in patients with CTCL. This agent works by binding to these receptors and subsequently delivering a toxic compound that interrupts protein synthesis within the cells, leading to their death. The FDA approved LYMPHIR in August 2024, recognizing its potential in treating this challenging cancer.

Citius successfully secured the rights to develop LYMPHIR globally, except in Japan and a few parts of Asia, further demonstrating their ambition to make a meaningful impact in the oncology space.

What is Cutaneous T-cell Lymphoma?

Cutaneous T-cell lymphoma is one of the most common forms of skin lymphoma, arising from T-cells implicated in the immune response. This condition can manifest in various ways and often leads to significant patient suffering due to a decline in quality of life stemming from painful skin lesions and chronic itching. Treatment options have traditionally been limited, and the disease is known to progress slowly, but can become aggressive and widespread over time.

For many patients, current therapies are not sufficient to control the disease, marking LYMPHIR as a crucial new weapon in the ongoing battle against CTCL. Notably, men are twice as likely to be diagnosed with CTCL compared to women, and it is predominantly identified in patients aged between 50 and 60 years.

Importance of the New Treatment

The introduction of LYMPHIR, alongside robust educational support for healthcare providers and patients, marks a pivotal moment for those afflicted by CTCL. As Citius Oncology prepares for the impending commercial launch, patient access and awareness are central to their mission.

In conclusion, this strategic relationship with McKesson highlights Citius Oncology's efforts to ensure that LYMPHIR is accessible to the patients who need it, reflecting their overarching commitment to improving the treatment landscape for Cutaneous T-cell lymphoma.

For further information on LYMPHIR and Citius Oncology's other initiatives, visit their official website.